Hyloris Pharmaceuticals prepared to go public

Reformulation specialist Hyloris Pharmaceuticals SA  wants to go public on the regulated market of Euronext Brussels. The company reformulates already approved pharmaceutical products using a proprietary technology, which it believes to offer significant advantages compared to currently available alternatives.

Currently, Hyloris has two early-stage commercial products and twelve product candidates in various stages of development, with a particular focus on injected cardiovascular products. The commercial products, namely Maxigesic IV and Sotalol IV, are expected to generate short-term revenue growth until additional products can be launched. Hyloris has already identified, reformulated and tested several product candidates to build its pipeline

Hyloris’ management team has a lot of experience in managing and growing pharma companies that develop drugs and bring them to the market. According to CEO and cofounder Stijn Van Rompay,  “Hyloris’ goal is to bring reformulated drugs with added value to the healthcare system as quickly as possible. We believe that there are significant opportunities to address unmet needs, utilising the established 505(b)(2) pathway.”      

Part of the proceeds of the IPO will be used to establish a sales team in the US. The price range, as well as other details of the offering will be published when the offering period is expected to commence. The IPO will include an offer to the public in Belgium as well as a private placement to qualified investors. KBC Securities and Kempen & Co are acting as Joint Global Coordinators and Joint Bookrunners.